Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Metabolism - Clinical and Experimental |
| Vol/bind | 58 |
| Udgave nummer | 8 |
| Sider (fra-til) | 1109-15 |
| Antal sider | 6 |
| ISSN | 0026-0495 |
| DOI | |
| Status | Udgivet - 2009 |
Bibliografisk note
Keywords: Aged; Appetite Depressants; Bilirubin; Biological Markers; Cardiovascular Diseases; Confounding Factors (Epidemiology); Cyclobutanes; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Overweight; Research Design; Risk Assessment; Risk Factors; Treatment Outcome; Weight LossAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
I: Metabolism - Clinical and Experimental, Bind 58, Nr. 8, 2009, s. 1109-15.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial
AU - Andersson, Charlotte
AU - Weeke, Peter
AU - Fosbøl, Emil Loldrup
AU - Brendorp, Bente
AU - Køber, Lars
AU - Coutinho, Walmir
AU - Sharma, Arya M
AU - Van Gaal, Luc
AU - Finer, Nick
AU - James, W Philip T
AU - Caterson, Ian D
AU - Rode, Richard A
AU - Torp-Pedersen, Christian
AU - SCOUT Executive Steering Committee
AU - SCOUT investigators
AU - Andersson, Charlotte
AU - Weeke, Peter
AU - Fosbøl, Emil Loldrup
AU - Brendorp, Bente
AU - Køber, Lars
AU - Coutinho, Walmir
AU - Sharma, Arya M
AU - Van Gaal, Luc
AU - Finer, Nick
AU - James, W Philip T
AU - Caterson, Ian D
AU - Rode, Richard A
AU - Torp-Pedersen, Christian
AU - Torp-Pedersen, Christian Tobias
AU - Torp-Pedersen, Christian Tobias
N1 - Keywords: Aged; Appetite Depressants; Bilirubin; Biological Markers; Cardiovascular Diseases; Confounding Factors (Epidemiology); Cyclobutanes; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Overweight; Research Design; Risk Assessment; Risk Factors; Treatment Outcome; Weight Loss
PY - 2009
Y1 - 2009
N2 - Low levels of bilirubin are associated with an increased risk of cardiovascular adverse events. Weight reduction is known to reduce several cardiovascular risk factors, but effects on bilirubin levels have not been reported. We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population. Data from the first 4 weeks of the lead-in period of the Sibutramine Cardiovascular Outcome study were analyzed. A total of 10 198 patients provided body weight measurements before and after 4 weeks of sibutramine treatment (10 mg daily), of whom 1059 (10.4%) gained weight, 1467 (13.7%) lost greater than 0% to 1%, 2492 (23.2%) lost greater than 1% to 2%, 2280 (21.2%) lost greater than 2% to 3%, 1498 (13.9%) lost greater than 3% to 4%, and 1402 (13.1%) lost greater than 4% of their initial weight, respectively. At screening, bilirubin concentrations were similar between weight loss groups (around 11 micromol/L, P = .7) and increased linearly as a function of weight loss. The effect was significantly more pronounced in men compared with women (P for interaction = .003). Adjusted for multiple variables, each 1% increase in weight loss was associated with 0.21-micromol/L (+/- standard error 0.027) increase in men (P < .0001) and 0.11-micromol/L (+/-0.024) increase in women (P < .0001). Short-term weight loss during administration of sibutramine in combination with diet and exercise advice is effective in increasing bilirubin levels within the reference range, with bilirubin increasing as a linear function of weight change. The effect is greater in men than in women.
AB - Low levels of bilirubin are associated with an increased risk of cardiovascular adverse events. Weight reduction is known to reduce several cardiovascular risk factors, but effects on bilirubin levels have not been reported. We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population. Data from the first 4 weeks of the lead-in period of the Sibutramine Cardiovascular Outcome study were analyzed. A total of 10 198 patients provided body weight measurements before and after 4 weeks of sibutramine treatment (10 mg daily), of whom 1059 (10.4%) gained weight, 1467 (13.7%) lost greater than 0% to 1%, 2492 (23.2%) lost greater than 1% to 2%, 2280 (21.2%) lost greater than 2% to 3%, 1498 (13.9%) lost greater than 3% to 4%, and 1402 (13.1%) lost greater than 4% of their initial weight, respectively. At screening, bilirubin concentrations were similar between weight loss groups (around 11 micromol/L, P = .7) and increased linearly as a function of weight loss. The effect was significantly more pronounced in men compared with women (P for interaction = .003). Adjusted for multiple variables, each 1% increase in weight loss was associated with 0.21-micromol/L (+/- standard error 0.027) increase in men (P < .0001) and 0.11-micromol/L (+/-0.024) increase in women (P < .0001). Short-term weight loss during administration of sibutramine in combination with diet and exercise advice is effective in increasing bilirubin levels within the reference range, with bilirubin increasing as a linear function of weight change. The effect is greater in men than in women.
U2 - 10.1016/j.metabol.2009.04.003
DO - 10.1016/j.metabol.2009.04.003
M3 - Journal article
C2 - 19454355
SN - 0026-0495
VL - 58
SP - 1109
EP - 1115
JO - Metabolism - Clinical and Experimental
JF - Metabolism - Clinical and Experimental
IS - 8
ER -